UBS keeps USD 25.00 target for Amneal Pharmaceuticals stock
Published on 10/15/2026 at 21:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget, dates and valuation
- On October 1, 2026, UBS reiterated a Buy rating with a USD 25.00 target.
- Amneal will report third-quarter 2026 results on November 3, 2026 before market open.
- Amneal Pharmaceuticals stock costs EUR 17.25 at Lang & Schwarz on October 15, 2026 at 9:37 p.m. CEST.
- The company had a USD 6.2 billion market capitalization and a 39.69 P/E ratio on October 15, 2026.
UBS reiterated a Buy rating for Amneal Pharmaceuticals on October 1, 2026, with a USD 25.00 price target, according to Investing.com. That target stood 29.06 percent above the Nasdaq price of USD 19.37 on October 15, 2026. Amneal Pharmaceuticals stock was trading at EUR 17.25 at Lang & Schwarz on October 15, 2026 at 9:37 p.m. CEST.
Results arrive November 3
Amneal will report third-quarter 2026 results before the U.S. market opens on November 3, 2026, and plans an 8:30 a.m. ET webcast, according to GlobeNewswire. The release describes a portfolio of 300 complex generic, specialty and biosimilar medicines and more than 160 million prescriptions annually.
Amneal stock stays inside its range
The Nasdaq quote was last at USD 19.37 on October 15, 2026 at 3:43 p.m. ET, up 2.47 percent on the session. Its 52-week range was USD 9.75 to USD 21.18, placing the quote below the upper end while keeping it above the yearly low. The euro quotation was in after-hours trading in Berlin when the Lang & Schwarz timestamp was recorded.
Valuation and the next catalyst
Amneal had a USD 6.2 billion market capitalization and a 39.69 P/E ratio on October 15, 2026. The company operates in healthcare and specialty and generic drug manufacturing, with its primary listing on Nasdaq. The November 3 reporting date is the next scheduled corporate event that could update earnings, cash flow and the outlook.
Comparison with peers
AMRX (Nasdaq, USD): plus 2.47 percent, P/E 39.69, market capitalization USD 6.2 billion
Neurocrine Biosciences (Nasdaq, USD): plus 0.86 percent, P/E 20.06, market capitalization USD 13.9 billion
Teva Pharmaceutical Industries (Nasdaq, USD): plus 1.55 percent, P/E 69.50, market capitalization USD 48.2 billion
Euro quote after hours
For German investors, Amneal Pharmaceuticals stock stood at EUR 17.25 at Lang & Schwarz on October 15, 2026 at 9:37 p.m. CEST. The next hard reference point is the third-quarter report scheduled for November 3, 2026.
The further course of trading is shown by the continuously updated real-time quote of Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals market data
- Company: Amneal Pharmaceuticals, Inc.
- ISIN: US03168L1052
- WKN: A2JLMD
- Ticker: AMRX
- Primary exchange: Nasdaq
- Price Lang & Schwarz: EUR 17.25 (as of October 15, 2026, 9:37 p.m. CEST)
- Nasdaq price: USD 19.37 (as of October 15, 2026, 3:43 p.m. ET)
- Nasdaq change: plus 2.47 percent on October 15, 2026
- Market capitalization: USD 6.2 billion (as of October 15, 2026)
- 52-week range: USD 9.75-21.18 (as of October 15, 2026)
- Sector / Industry: Healthcare / specialty and generic drug manufacturing
- Next earnings date: November 3, 2026
Market context: Market report Nasdaq Composite.
